Xin Li, M.D., Ph.D.
Investigator
Dr. Xin Li, M.D., Ph.D., is a board‑certified hematologist and medical oncologist with extensive clinical and research experience spanning more than two decades. She currently serves as a physician with the Sutter East Bay Medical Group and co‑director of the Carol Ann Reed Breast Cancer Program. Dr. Li completed her Hematology/Oncology Fellowship at the University of Southern California and her Internal Medicine Residency at Greater Baltimore Medical Center. She earned both her medical degree and master’s degree from Peking University Health Science Center and holds a Ph.D. in Molecular and Cellular Pathology from the University of Alabama at Birmingham, where she also completed postdoctoral research.
Dr. Li has authored numerous peer‑reviewed publications focused on cancer biology and growth factor signaling. She is an active member of the American Society of Clinical Oncology and multiple regional oncology organizations, dedicated to advancing patient‑centered cancer care.
Clinical trials
- Clinical trial
Adjuvant Breast NRG-BR009
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Status: Open to Enrollment
- Clinical trial
Adjuvant Large B-Cell Lymphoma Alpha3
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
Status: Open to Enrollment
- Clinical trial
Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Status: Open to Enrollment
- Clinical trial
Adverse Effects of Chemotherapy Shengbai Solution
A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Breast Cancer SWOG S2206
Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for MammaPrint Ultrahigh (PM2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Status: Open to Enrollment